Merck Initiates Phase 3 Clinical program for Oral PCSK9 Inhibitor Candidate MK-0616
RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced the initiation of the company's Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral...
Source: marketscreener.com